DarioHealth (Nasdaq:DRIO) announced today that it agreed with Dexcom (Nasdaq:DXCM) to integrate continuous glucose monitoring into its digital health platform.
Dexcom CGM uses small, wearable sensors to continuously measure and send glucose levels to a receiver or smart device. The company’s latest CGM technology, the Dexcom G7, recently received FDA clearance. The company plans to announce its U.S. launch in a commercial during the Super Bowl on Feb. 12.
The agreement between DarioHealth and Dexcom enables the integration of CGM data into DarioHealth’s chronic condition platform. This allows users of the wearable device to benefit from DarioHealth’s personalized digital therapeutic support.
DarioHealth’s integrated platform provides personalized support through clinical, engagement and behavioral data. It adapts each user’s experience over time. Using CGM enables even more personalization and guidance for the users, DarioHealth said in a news release.
“Nearly 2 million people use a continuous glucose monitor today, and the ability to capture that data in Dario’s platform expands our ability to deliver a dynamic, highly relevant experience to more people living with diabetes,” said DarioHealth President Rick Anderson. “It’s an exciting development that will ultimately benefit every Dario member as the CGM data enriches our overall data ecosystem.”
DarioHealth said this integration builds upon the collaboration with Sanofi that it announced last year. That partnership aims to establish an ecosystem of dedicated technology partners and digital therapeutic solutions.
“We’re proud of our ongoing collaboration with Sanofi U.S. which is helping Dario to establish new innovations to meet the needs of our customers and members as demonstrated by this Dexcom integration,” Anderson added.
